FEATURE: Genomics Sector, Entering Adolescence, Girds for a Realignment in 2002 | GenomeWeb

NEW YORK, Dec. 26 - Sequencing the human genome was widely expected to produce a wealth of new drug targets, and the genomics startups that burst onto the scene in recent years have largely delivered. As a result, the research market for genomics companies is vibrant: Worth just $2 billion two years ago, the market is poised to reach $8 billion by 2004, the need for better technology and marketable drugs and diagnostics fueling the growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.